Emergent BioSolutions (EBS) Free Cash Flow (2010 - 2026)

Emergent BioSolutions' Free Cash Flow history runs 17 years deep, the most recent figure standing at -$36.2 million for Q1 2026.

• On a quarterly basis, Free Cash Flow fell 144.59% year-over-year to -$36.2 million in Q1 2026; TTM through Mar 2026 was $147.6 million, a 69.85% increase from a year earlier, with the FY2025 full-year figure at $169.0 million, up 372.07% from the prior year.
• Free Cash Flow retreated to -$36.2 million in Q1 2026 per EBS's latest filing, from $77.9 million in the prior quarter.
• Across five years, Free Cash Flow topped out at $175.6 million in Q4 2022 and bottomed at -$191.8 million in Q1 2023.
• The 5-year median for Free Cash Flow is -$14.8 million (2025), against an average of -$7.8 million.
• Across the five-year window, Free Cash Flow tumbled 692.23% in 2024 and surged 195.47% in 2025, its largest moves.
• Year by year, Free Cash Flow stood at $175.6 million in 2022, then slumped by 105.87% to -$10.3 million in 2023, then tumbled by 692.23% to -$81.6 million in 2024, then jumped by 195.47% to $77.9 million in 2025, then slumped by 146.47% to -$36.2 million in 2026.
• Per Business Quant, the three latest EBS Free Cash Flow figures stand at -$36.2 million (Q1 2026), $77.9 million (Q4 2025), and $2.4 million (Q3 2025).